The third edition of The Process of New Drug Discovery and Development presents a practical methodology and up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace.
The third edition of The Process of New Drug Discovery and Development presents a practical methodology and up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace.
Acknowledgments Introduction to the First Edition (1992) Introduction to the Second Edition (2006) Editors Contributors Chapter 1 Introduction to Drug Discovery and Development James J. O'Donnell III, John C. Somberg, and James T. O'Donnell SECTION I Overview Chapter 2 Current Opinions on the Trajectory of the Pharmaceutical Development John C. Somberg Chapter 3 Innovation in Drug Development: Perspectives of a Venture Capitalist Krishna Yeshwant SECTION II Drug Discovery Chapter 4 High-Throughput Screening Omar Perez, J. Pena, Virneliz Fernandez-Vega, Louis Scampavia, and Timothy Spicer Chapter 5 DNA-Encoded Compound Libraries: An Emerging Paradigm in Drug Hit Discovery Raphael M. Franzini Chapter 6 Bio-Targeted Nanomaterials for Theranostic Applications Sabyasachi Maiti and Kalyan Kumar Sen Chapter 7 The Development of Adoptive T-Cell Immunotherapies for Cancer: Challenges and Prospects David J. Dow, Steven J. Howe, Mala K. Talekar, and Laura A. Johnson Chapter 8 CRISPR in Drug Discovery Chih-Shia Lee and Ji Luo Chapter 9 Probiotics in the World: "Bugs-as-Drugs" Thomas Kuntz, Madeline Kim, Elle Simone Hill, Mariana C. Salas Garcia, and Jack A. Gilbert Chapter 10 Discovery and Early Development of the Next-Generation ALK Inhibitor, Lorlatinib (18): Agent for Non?Small-Cell Lung Cancer Paul F. Richardson SECTION III Drug Development Chapter 11 Integrated Drug Product Development: From Lead Candidate Selection to Life-Cycle Management Madhu Pudipeddi, Abu T.M. Serajuddin, Ankita V. S
Acknowledgments Introduction to the First Edition (1992) Introduction to the Second Edition (2006) Editors Contributors Chapter 1 Introduction to Drug Discovery and Development James J. O'Donnell III, John C. Somberg, and James T. O'Donnell SECTION I Overview Chapter 2 Current Opinions on the Trajectory of the Pharmaceutical Development John C. Somberg Chapter 3 Innovation in Drug Development: Perspectives of a Venture Capitalist Krishna Yeshwant SECTION II Drug Discovery Chapter 4 High-Throughput Screening Omar Perez, J. Pena, Virneliz Fernandez-Vega, Louis Scampavia, and Timothy Spicer Chapter 5 DNA-Encoded Compound Libraries: An Emerging Paradigm in Drug Hit Discovery Raphael M. Franzini Chapter 6 Bio-Targeted Nanomaterials for Theranostic Applications Sabyasachi Maiti and Kalyan Kumar Sen Chapter 7 The Development of Adoptive T-Cell Immunotherapies for Cancer: Challenges and Prospects David J. Dow, Steven J. Howe, Mala K. Talekar, and Laura A. Johnson Chapter 8 CRISPR in Drug Discovery Chih-Shia Lee and Ji Luo Chapter 9 Probiotics in the World: "Bugs-as-Drugs" Thomas Kuntz, Madeline Kim, Elle Simone Hill, Mariana C. Salas Garcia, and Jack A. Gilbert Chapter 10 Discovery and Early Development of the Next-Generation ALK Inhibitor, Lorlatinib (18): Agent for Non?Small-Cell Lung Cancer Paul F. Richardson SECTION III Drug Development Chapter 11 Integrated Drug Product Development: From Lead Candidate Selection to Life-Cycle Management Madhu Pudipeddi, Abu T.M. Serajuddin, Ankita V. S
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
